Alpharma ANDA Approvals On Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Approvals of Alpharma ANDAs for oral solid dose formulations are on hold "pending a successful follow-up inspection" by FDA of an Elizabeth, N.J. manufacturing facility, the company said May 7.
You may also be interested in...
Teva, Ivax Move Closer To Marketing Generic Gabapentin; Neurontin Litigation Continues
Ivax receives full ANDA approval for low dose tablet formulations of gabapentin. Teva licenses Alpharma's generic exclusivity for capsule form and higher dose tablets.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.